These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 38562939)

  • 1. Impact of programmed cell death protein 1 inhibitor therapy on the survival of patients with advanced or recurrent uterine cancers: a meta-analysis.
    Liang KW; Chen LJ; Wang CH; Ma KS; Hsia LH; Wang PH
    Front Immunol; 2024; 15():1331994. PubMed ID: 38562939
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Incorporation of anti-PD1 or anti PD-L1 agents to platinum-based chemotherapy for the primary treatment of advanced or recurrent endometrial cancer. A meta-analysis.
    Bartoletti M; Montico M; Lorusso D; Mazzeo R; Oaknin A; Musacchio L; Scambia G; Puglisi F; Pignata S
    Cancer Treat Rev; 2024 Apr; 125():102701. PubMed ID: 38422895
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy of immune-checkpoint inhibitors combined with cytotoxic chemotherapy in advanced or recurrent endometrial cancer: A systematic review and meta-analysis.
    Kim JH; Han KH; Park EY; Kim ET; Kim EJ; Tan DSP; Lee JY; Park SY; Fotopoulou C; Lim MC
    Gynecol Oncol; 2024 Aug; 187():85-91. PubMed ID: 38735144
    [TBL] [Abstract][Full Text] [Related]  

  • 4. PD-1/PD-L1 inhibitors plus carboplatin and paclitaxel compared with carboplatin and paclitaxel in primary advanced or recurrent endometrial cancer: a systematic review and meta-analysis of randomized clinical trials.
    de Moraes FCA; Pasqualotto E; Lopes LM; Cavalcanti Souza ME; de Oliveira Rodrigues ALS; de Almeida AM; Stecca C; Fernandes MR; Dos Santos NPC
    BMC Cancer; 2023 Nov; 23(1):1166. PubMed ID: 38031003
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical benefit analysis of PD-1 inhibitors in patients with advanced, recurrent or metastatic cervical cancer: a meta-analysis and systematic review.
    Wang YZ; Wang JS; Du J; Tang XL; Xiao JP
    Front Immunol; 2024; 15():1305810. PubMed ID: 38327524
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical benefits of PD-1 inhibitors in specific subgroups of patients with advanced esophageal squamous cell carcinoma: a systematic review and meta-analysis of phase 3 randomized clinical trials.
    Lu Y; Wang W; Wang F
    Front Immunol; 2023; 14():1171671. PubMed ID: 37205107
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The relationship between blood-based tumor mutation burden level and efficacy of PD-1/PD-L1 inhibitors in advanced non-small cell lung cancer: a systematic review and meta-analysis.
    Ba H; Liu L; Peng Q; Chen J; Zhu YD
    BMC Cancer; 2021 Nov; 21(1):1220. PubMed ID: 34774004
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Factors Modifying the Associations of Single or Combination Programmed Cell Death 1 and Programmed Cell Death Ligand 1 Inhibitor Therapies With Survival Outcomes in Patients With Metastatic Clear Cell Renal Cell Carcinoma: A Systematic Review and Meta-analysis.
    Sati N; Boyne DJ; Cheung WY; Cash SB; Arora P
    JAMA Netw Open; 2021 Jan; 4(1):e2034201. PubMed ID: 33496794
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Association of Survival and Immune-Related Biomarkers With Immunotherapy in Patients With Non-Small Cell Lung Cancer: A Meta-analysis and Individual Patient-Level Analysis.
    Yu Y; Zeng D; Ou Q; Liu S; Li A; Chen Y; Lin D; Gao Q; Zhou H; Liao W; Yao H
    JAMA Netw Open; 2019 Jul; 2(7):e196879. PubMed ID: 31290993
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Predictive Values of Programmed Cell Death-Ligand 1 Expression for Prognosis, Clinicopathological Factors, and Response to Programmed Cell Death-1/Programmed Cell Death-Ligand 1 Inhibitors in Patients With Gynecological Cancers: A Meta-Analysis.
    Zhang C; Yang Q
    Front Oncol; 2020; 10():572203. PubMed ID: 33634012
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effectiveness and tolerability of programmed cell death protein-1 inhibitor + chemotherapy compared to chemotherapy for upper gastrointestinal tract cancers.
    Zhang XM; Yang T; Xu YY; Li BZ; Shen W; Hu WQ; Yan CW; Zong L
    World J Gastrointest Oncol; 2024 Apr; 16(4):1613-1625. PubMed ID: 38660631
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immune checkpoint inhibitors
    Liu S; Dou L; Li S
    Therap Adv Gastroenterol; 2024; 17():17562848241233134. PubMed ID: 38425370
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and safety of PD-1 inhibitors combined with chemotherapy as first-line therapy for advanced esophageal cancer: A systematic review and network meta-analysis.
    Li ZC; Sun YT; Lai MY; Zhou YX; Qiu MZ
    Int Immunopharmacol; 2022 Aug; 109():108790. PubMed ID: 35504202
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Soluble PD-L1 changes in advanced non-small cell lung cancer patients treated with PD-1 inhibitors: an individual patient data meta-analysis.
    Shimizu T; Inoue E; Ohkuma R; Kobayashi S; Tsunoda T; Wada S
    Front Immunol; 2023; 14():1308381. PubMed ID: 38115995
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic significance of programmed cell death-ligand 1 expression on circulating tumor cells in various cancers: A systematic review and meta-analysis.
    Ouyang Y; Liu W; Zhang N; Yang X; Li J; Long S
    Cancer Med; 2021 Oct; 10(20):7021-7039. PubMed ID: 34423578
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and safety of PD-1/PD-L1 inhibitors combined with anti-angiogenic therapy for the unresectable hepatocellular carcinoma and the benefit for hepatitis B virus etiology subgroup: a systematic review and meta-analysis of randomized controlled trials.
    Huang D; Ke L; Cui H; Li S
    BMC Cancer; 2023 May; 23(1):474. PubMed ID: 37226111
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Reconstruction of unreported subgroup survival data with PD-L1-low expression in advanced/metastatic triple-negative breast cancer using innovative KMSubtraction workflow.
    Li Y; Liang X; Li H; Chen X
    J Immunother Cancer; 2024 Jan; 12(1):. PubMed ID: 38212119
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Association of Cyclin-Dependent Kinases 4 and 6 Inhibitors With Survival in Patients With Hormone Receptor-Positive Metastatic Breast Cancer: A Systematic Review and Meta-analysis.
    Li J; Huo X; Zhao F; Ren D; Ahmad R; Yuan X; Du F; Zhao J
    JAMA Netw Open; 2020 Oct; 3(10):e2020312. PubMed ID: 33048129
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immune checkpoint inhibitors efficacy across solid cancers and the utility of PD-L1 as a biomarker of response: a systematic review and meta-analysis.
    Fitzsimmons TS; Singh N; Walker TDJ; Newton C; Evans DGR; Crosbie EJ; Ryan NAJ
    Front Med (Lausanne); 2023; 10():1192762. PubMed ID: 37250628
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparative efficacy and safety of PD-1/PD-L1 Inhibitors versus platinum-based chemotherapy for the first-line treatment of advanced non-small cell lung cancer: a meta analysis of randomized controlled trials.
    Li ZQ; Yan HC; Gu JJ; Yang YL; Zhang MK; Fang XJ
    Pharmacol Res; 2020 Oct; 160():105194. PubMed ID: 32937178
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.